Synopsis: A once-premium engineering services stock has lost nearly half its value in a year. Behind the fall lies a familiar story of margin pressure, missed recovery targets in a key vertical, and slowing growth aspirations that management has quietly scaled back.
The stock has lost nearly half its value over the past year, making it one of the worst performers among India’s engineering and design services companies. It has declined from a 52-week high of ₹6,439.50 on July 16, 2025, to around ₹3,500, while remaining well below its all-time high of ₹10,700.
While part of this correction reflects a broader IT services de-rating, a closer look at the company’s own numbers over the last two quarters shows that the business itself has been struggling on several fronts. Here’s a data-backed breakdown of what went wrong.
Margins Have Collapsed Sharply, Even As Revenue “Grew”
Tata Elxsi’s Q1 FY27 results, for the quarter ended June 30, 2026, looked healthy on the surface. Reported revenue came in at ₹1,021.1 crore, up 2.8% QoQ and 14.5% YoY. But scratch beneath the headline number and the picture changes. In constant currency terms, revenue grew just 1.3% QoQ and 6.5% YoY – meaning a large chunk of the reported growth came from currency tailwinds, not real business momentum.
More worrying is the sharp margin compression. EBITDA margin fell to 21.2% in Q1 FY27, down from 24.6% in Q4 FY26 – a drop of roughly 340 basis points in a single quarter. PBT margin slid to 21.9% from 25.6% QoQ, and PBT itself fell 13.2% QoQ to ₹232.5 crore. Profit after tax dropped 22.6% QoQ to ₹170.6 crore, even though it was still up 18.2% YoY. For a company long known for industry-leading margins, this kind of sequential erosion has clearly spooked investors.
Healthcare Vertical Continues To Disappoint Despite Repeated Assurances
During the Q4 FY26 earnings call held on April 21, 2026, management had repeatedly reassured investors that the Healthcare and Life Sciences vertical, which had de-grown 13.1% QoQ in constant currency that quarter, had “hit the bottom” and deals worth signing were in an advanced stage. CEO Manoj Raghavan specifically said he was “pretty hopeful” of a recovery in Q1 FY27, with delayed deals from as far back as October 2025 expected to close.
The actual Q1 FY27 numbers tell a different story. Healthcare and Life Sciences revenue was down 22.1% year-on-year in constant currency, and grew a marginal 1.7% QoQ (down 0.3% in CC terms) – nowhere close to the recovery management had guided for. This pattern of repeatedly pushed-out healthcare recovery, first from Q3 to Q4, and then from Q4 to Q1, appears to have dented investor confidence in management’s forward guidance.
Transportation Growth Aspirations Have Been Scaled Back
Transportation, the company’s largest vertical at over 55% of SDS revenue, has also underwhelmed. In the April call, management spoke of aiming for double-digit growth in the automotive business for FY27, though even then they flagged that a “high-single digit exit” was more realistic given geopolitical uncertainty.
By Q1 FY27, transportation revenue actually declined 0.4% QoQ in constant currency, even as OEM customers grew to represent 78% of automotive revenue, up from 77% earlier. Management’s overall FY27 growth aspiration has now been quietly downgraded from “double-digit” to “higher single digit,” a meaningful reset of expectations that markets typically punish.
Shrinking Headcount And Rising Attrition Signal Deeper Stress
Employee metrics add to the concern. Headcount has fallen every single quarter for the past year, from 12,127 in Q1 FY26 to 11,336 in Q1 FY27 – a decline of nearly 800 employees. At the same time, attrition has been creeping up steadily, from 15.0% to 16.0% over the same period. In a services business, shrinking headcount alongside rising attrition, without a corresponding surge in utilization-led profitability, is often read by analysts as a sign of soft demand rather than pure operating efficiency
Client Concentration Has Increased
Revenue dependence on top clients has also risen. The top 5 clients now contribute 49.2% of revenue, up from 44.7% a year ago, while the top 10 clients account for 59.7%, up from 54.6%. Rising client concentration adds an element of revenue-risk that investors typically demand a valuation discount for, especially when growth itself is decelerating.
The Bigger Picture
Put together, these factors – a sharp sequential margin decline, a healthcare vertical that keeps missing its own recovery timelines, transportation growth guidance being walked back, a shrinking workforce with rising attrition, and increasing client concentration – help explain why the stock has been re-rated so severely from its 2025 highs. Management remains publicly optimistic about FY27 being a “growth year,” but the last two quarters suggest the market wants to see consistent delivery before it re-rates the stock higher again.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
